Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897375 · ClinicalTrials.gov registry record · Phase 1
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT02897375 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 71 participants.
The verdict
NCT02897375, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib with cisplatin or carboplatin may help stop tumor growth in patients with advanced solid tumors.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Palbociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2016-10-24 |
| Est. Completion | 2021-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02897375
The ClinicalTrials.gov registry entry for NCT02897375 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02897375 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02897375 about?
NCT02897375 is a clinical study titled "Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors". This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of ...
What is the current status of trial NCT02897375?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2016-10-24. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT02897375?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02897375?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.